Temasek, Singapore's state investor, and private equity firm Warburg Pincus are preparing to sell Global Healthcare Exchange (GHX), a healthcare supply chain management company, with an anticipated valuation of nearly $5 billion. This information comes from a Financial Times report citing sources familiar with the situation.

GHX has enlisted advisors to manage the sale process, which may involve either a partial divestment or a complete exit. Formal bids for the company are expected to be submitted in the latter half of the year.

Temasek initially invested in GHX in 2017, when the company was valued at $1.8 billion. GHX specializes in providing cloud-based solutions for inventory, supply chain, and payment management tailored for healthcare providers and suppliers. Warburg Pincus took a minority stake in GHX in 2021, investing $500 million, which allowed previous minority investor Thoma Bravo to exit. Thoma Bravo had acquired GHX in 2014.

Founded in 2000, GHX has established itself as a leader in healthcare's cloud-based supply chain network, connecting tens of thousands of healthcare organizations worldwide. The company claims to enhance the efficiency and effectiveness of the healthcare ecosystem.

The potential sale of GHX is likely to attract interest from both private equity firms and strategic buyers, although sources indicate that a deal is not guaranteed.